Literature DB >> 17984802

Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions.

Claire-Anne Siegrist1, Edwin M Lewis, Juhani Eskola, Stephen J W Evans, Steven B Black.   

Abstract

BACKGROUND: The large-scale implementation of human papilloma virus (HPV) immunization will be followed by cases of autoimmune diseases occurring in temporal association with immunizations. To anticipate events that might be mistakenly assumed to be caused by immunization, their prevalence was monitored before vaccine introduction.
METHOD: Cohort study carried out within a database of female adolescents (n = 214,896) and young adults (n = 221,472) followed in the pre-HPV vaccine era (2005), computing rates of emergency consultations, hospitalizations and outpatient consultations, and estimation of risks of coincident associations.
RESULTS: Immune-mediated conditions were a frequent cause (10.3%) of emergency room consultation by adolescent girls. Nonallergic immune-mediated conditions affected 86 per 100,000, diabetes ranking first. In 2005, 53 per 100,000 adolescents and 389 per 100,000 women were hospitalized for diseases of presumed autoimmune origin, thyroiditis being the most frequent diagnosis. If HPV immunization had been used with 80% coverage, 3 per 100,000 adolescents would have required emergency care for asthma/allergy within 24 hours and 2 per 100,000 for diabetes within 1 week of an injection. The risks of hospitalization in temporal association with immunization are 4 times higher for thyroiditis than for multiple sclerosis or Guillain-Barré's syndrome, and more than 20 times higher in young women than in adolescents.
CONCLUSION: The distinction between HPV vaccine-caused adverse reactions and events only observed by chance in temporal association is difficult. The prior use of population-based data allows for identification of issues of potential concern, for monitoring the impact of large-scale interventions and for addressing rapidly vaccine-safety issues that may compromise vaccine programs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984802     DOI: 10.1097/INF.0b013e318149dfea

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  29 in total

1.  Pharmacoepidemiology.

Authors:  Stephen J W Evans
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Autoimmune diseases after adolescent or adult immunization: what should we expect?

Authors:  Claire-Anne Siegrist
Journal:  CMAJ       Date:  2007-11-20       Impact factor: 8.262

3.  [Nobel price for vaccination against cervical cancer: current data and guidelines].

Authors:  H M Hepburn; A M Kaufmann
Journal:  Internist (Berl)       Date:  2009-05       Impact factor: 0.743

4.  No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus.

Authors:  Paolo Pellegrino; Carla Carnovale; Valentina Perrone; Stefania Antoniazzi; Marco Pozzi; Emilio Clementi; Sonia Radice
Journal:  Eur J Epidemiol       Date:  2013-07-18       Impact factor: 8.082

5.  "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events.

Authors:  David Evans; Simon Cauchemez; Frederick G Hayden
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

6.  Background rates of disease in Latin American children from a rotavirus vaccine study.

Authors:  Marc Baay; Kaatje Bollaerts; Claudio Struchiner; Thomas Verstraeten
Journal:  Hum Vaccin Immunother       Date:  2017-04-25       Impact factor: 3.452

7.  Overcoming barriers in HPV vaccination and screening programs.

Authors:  Alex Vorsters; Marc Arbyn; Marc Baay; Xavier Bosch; Silvia de Sanjosé; Sharon Hanley; Emilie Karafillakis; Pier Luigi Lopalco; Kevin G Pollock; Joanne Yarwood; Pierre Van Damme
Journal:  Papillomavirus Res       Date:  2017-07-20

Review 8.  [Prophylactic and therapeutic vaccines against human papilloma virus].

Authors:  A E Albers; T K Hoffmann; J P Klussmann; A M Kaufmann
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

9.  Anaphylaxis following quadrivalent human papillomavirus vaccination.

Authors:  Julia M L Brotherton; Mike S Gold; Andrew S Kemp; Peter B McIntyre; Margaret A Burgess; Sue Campbell-Lloyd
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

10.  Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study.

Authors:  Liew Woei Kang; Nigel Crawford; Mimi L K Tang; Jim Buttery; Jenny Royle; Michael Gold; Christine Ziegler; Patrick Quinn; Sonja Elia; Sharon Choo
Journal:  BMJ       Date:  2008-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.